Phase 3 Upadacitinib Study Achieves Positive Results for the Treatment of Giant Cell Arteritis

Results of the SELECT-GCA study demonstrated approximately half of patients with giant cell arteritis treated with upadacitinib plus a steroid tapering regimen were able to achieve sustained remission through week 52.

Related Keywords

Leuven ,Region Flamande ,Belgium ,Gasthuisberg ,Daniel Blockmans ,Kori Wallace ,Medicine At University Hospitals Gasthuisberg ,General Internal Medicine ,University Hospitals Gasthuisberg ,